Similarly, expression of IL-33 was found to be increased when compared to adjacent healthy tissue in patients with both non-small-cell lung carcinoma (NSCLC) (87) and epithelial ovarian cancer (88). This evidence concerns the gene IL33 and non-small cell lung carcinoma.